Skip to Content

BioCryst Pharmaceuticals Inc BCRX

Morningstar Rating
$5.79 +0.08 (1.40%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

BCRX is trading at a 33% discount.
Price
$5.74
Fair Value
$10.00
Uncertainty
Extreme
1-Star Price
$15.45
5-Star Price
$7.24
Economic Moat
Bmq
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BCRX is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$5.71
Day Range
$5.646.03
52-Week Range
$4.839.20
Bid/Ask
$5.72 / $5.80
Market Cap
$1.19 Bil
Volume/Avg
4.0 Mil / 4.2 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
3.31
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, with the aim of blocking key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
531

Comparables

Valuation

Metric
BCRX
ENTA
AVIR
Price/Earnings (Normalized)
Price/Book Value
1.460.58
Price/Sales
3.313.77
Price/Cash Flow
Price/Earnings
BCRX
ENTA
AVIR

Financial Strength

Metric
BCRX
ENTA
AVIR
Quick Ratio
4.976.0431.50
Current Ratio
5.546.2531.93
Interest Coverage
−1.26
Quick Ratio
BCRX
ENTA
AVIR

Profitability

Metric
BCRX
ENTA
AVIR
Return on Assets (Normalized)
−38.81%−27.96%−14.35%
Return on Equity (Normalized)
−47.34%−14.90%
Return on Invested Capital (Normalized)
−29.51%−44.45%−18.26%
Return on Assets
BCRX
ENTA
AVIR
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRRqnm$550.2 Bil
VRTX
Vertex Pharmaceuticals IncXwczrb$112.0 Bil
REGN
Regeneron Pharmaceuticals IncJgmymb$108.6 Bil
MRNA
Moderna IncKrsq$35.9 Bil
ARGX
argenx SE ADRCkg$24.2 Bil
BNTX
BioNTech SE ADRPjmj$22.2 Bil
ALNY
Alnylam Pharmaceuticals IncXglzqvg$20.0 Bil
BMRN
Biomarin Pharmaceutical IncZfddmq$17.0 Bil
RPRX
Royalty Pharma PLC Class AJbcdstx$14.0 Bil
INCY
Incyte CorpQtdgqmf$13.6 Bil

Sponsor Center